Detalhe da pesquisa
1.
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
Mol Cancer
; 23(1): 93, 2024 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38720314
2.
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Int J Mol Sci
; 25(7)2024 Apr 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38612799
3.
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Ann Hematol
; 102(2): 323-328, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36576532
4.
Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
Int J Mol Sci
; 24(17)2023 Aug 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37686200
5.
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis.
Int J Mol Sci
; 22(13)2021 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34209696
6.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer
; 145(3): 857-868, 2019 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30694523
7.
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Br J Haematol
; 183(2): 235-241, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30378121
8.
Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3).
J Biol Chem
; 290(42): 25275-92, 2015 Oct 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26296892
9.
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Br J Haematol
; 190(3): e169-e173, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32515072
10.
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Br J Haematol
; 169(5): 694-700, 2015 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-25818407
11.
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Blood
; 122(14): 2443-52, 2013 Oct 03.
Artigo
Inglês
| MEDLINE | ID: mdl-23982172
12.
Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.
Future Oncol
; 10(7): 1157-65, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24947257
13.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
J Thorac Oncol
; 19(5): 803-817, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38096950
14.
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Acta Haematol
; 129(2): 121-5, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23207728
15.
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Mol Cell Proteomics
; 10(12): M111.011635, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-21955398
16.
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Clin Lung Cancer
; 24(6): 568-572, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37169628
17.
Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
Cancer Biol Med
; 19(11)2022 12 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36476337
18.
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Lung Cancer
; 164: 46-51, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34998106
19.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Eur J Cancer
; 170: 106-118, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35598358
20.
Efferocytosis fuels malignant pleural effusion through TIMP1.
Sci Adv
; 7(33)2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34389533